HH
Haresh Hondraj Khetwani
About Haresh Hondraj Khetwani
Data last updated:
Haresh Hondraj Khetwani is a Director at Oncobiotek Formulations Private Limited (since 2018) and Director at Oncobiotek Drugs Private Limited (since 2014). The companies operate in Pharma. The 2 current companies with reported revenue have a combined latest revenue of ₹14.63 Cr; the largest is Oncobiotek Formulations Private Limited at ₹10.73 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Oncobiotek Formulations Private Limited U24290GJ2018PTC102902 | Director | 18 Jun 2018 | 2018 | ₹10.73 Cr (FY 2025) | Active |
 Oncobiotek Drugs Private Limited U24230GJ2014PTC079996 | Director | 03 Jul 2014 | 2014 | ₹3.90 Cr (FY 2025) | Active |
Board colleagues of Haresh Hondraj Khetwani
| Name | DIN | Company | Designation |
|---|---|---|---|
| Rajesh Omprakash Sharma | 06881952 | Oncobiotek Formulations Private Limited , Oncobiotek Drugs Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Haresh Hondraj Khetwani
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Haresh Hondraj Khetwani
Haresh Hondraj Khetwani currently holds 2 directorships: Oncobiotek Formulations Private Limited (Director, since 18 Jun 2018, revenue ₹10.73 Cr (FY 2025)); Oncobiotek Drugs Private Limited (Director, since 03 Jul 2014, revenue ₹3.90 Cr (FY 2025)).
Haresh Hondraj Khetwani was first appointed on 03 Jul 2014 as Director at Oncobiotek Drugs Private Limited. The most recent appointment on record is 18 Jun 2018 at Oncobiotek Formulations Private Limited.
The 2 current companies of Haresh Hondraj Khetwani that report revenue have a combined latest revenue of ₹14.63 Cr: Oncobiotek Formulations Private Limited ₹10.73 Cr (FY 2025); Oncobiotek Drugs Private Limited ₹3.90 Cr (FY 2025).
The current boards of Haresh Hondraj Khetwani's companies include Rajesh Omprakash Sharma (Oncobiotek Formulations Private Limited).